FARCO-PHARMA

What FARCO-PHARMA does

FARCO-PHARMA GmbH is a privately held German specialty pharmaceutical and medical-device company founded in 1964 and headquartered in Cologne, North Rhine-Westphalia. The company develops, manufactures, and distributes sterile urology-focused products organised in four categories: sterile lubricants (Instillagel®, Endosgel®, Instillido®, InstillaGel® Lubri, Instillaquill®, InstillaClip), instillation therapy (VESOXX®), the hydrogel method (mediNiK®), and sterile catheter inflation solutions (Farco-fill® Aqua-Glycerol). Its products support urological examinations, catheterization, neurogenic detrusor overactivity (NDO) management, kidney stone care, and urinary incontinence, serving hospitals, urology clinics, and specialist healthcare professionals, alongside patient-facing education resources.

The business model is hardware/product sales to healthcare providers and institutions, with pricing negotiated through institutional channels rather than publicly disclosed. Go-to-market is indirect and partner-driven: FARCO-PHARMA distributes through a network of more than 30 international sales partners to 60 countries, supplemented by direct engagement at more than 90 urology events and conferences per year. The company self-positions as the international market leader in sterile lubricants and instillation therapies and emphasises a "Quality, made in Germany" brand attribute backed by 60 years of continuous operation; clinical credibility is reinforced through co-development with Purenum GmbH and academic engagement with Charité Universitätsmedizin Berlin (notably the #NDOteenCamp initiative), as well as professional-society ties with the German Society of Urology (DGU) and Deutsche Kontinenzgesellschaft. A new femanea sub-brand signals initial expansion into a focused women's health / continence line within the existing urology franchise.

Name

FARCO-PHARMA

Legal name

FARCO-PHARMA GmbH

Website

https://farco-pharma.com

Company type

Private

Founded year

1964

Operating status

Operating

Headcount range

101–250 employees

Short description

FARCO-PHARMA GmbH is a Cologne-based, privately held German specialty pharmaceutical and medical-device company that develops and distributes sterile lubricants, instillation therapies, hydrogel-based devices, and catheter inflation solutions for urology specialists across 60 countries.

Ownership category

akta.pro rank

Product category

Urological Medical Devices

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

Keywords

• Urological medical devices
• Sterile lubricants
• Instillation therapy
• Catheter inflation solutions
• Medical device manufacturing

Headquarters

HQ city

Cologne

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Medical Device/Pharmaceutical Product Sales: FARCO-PHARMA generates revenue through the sale of sterile lubricants, instillation therapy products, hydrogel-based medical devices, and catheter inflation solutions to healthcare providers and institutions in the urology field.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

FARCO-PHARMA manufactures and sells specialized urological medical products, including sterile lubricants, instillation therapy solutions, hydrogel-based treatments, and catheter inflation devices. The company supplies healthcare providers, urology clinics, and hospitals internationally, with a focus on sterile single-use and specialty urology consumables.

Product overview

FARCO-PHARMA offers a focused medical device and pharmaceutical product portfolio comprising four product categories: (1) Sterile lubricants including Instillagel®, Endosgel®, Instillido®, InstillaGel® Lubri, Instillaquill®, and InstillaClip for urological and endoscopic procedures; (2) Instillation therapy with VESOXX®; (3) Hydrogel method featuring mediNiK®; and (4) Sterile catheter inflation solutions with Farco-fill® Aqua-Glycerol. The company positions itself as the international market leader in sterile lubricants and instillation therapies for urology and related specialties.

Differentiator

Problem solved

Functional benefit

Brands

• Instillagel®: Sterile lubricant product for urological procedures
• Endosgel®
• Instillido®
• InstillaGel® Lubri
• Instillaquill®
• InstillaClip
• mediNiK®
• VESOXX®
• Farco-fill® Aqua-Glycerol
• femanea
• Hydrogel-Method

Products and services

• Sterile urological lubricants
• Instillation therapy products
• Hydrogel-based urological treatments
• Catheter inflation solutions

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Purenum GmbHcoreStrategic or Co-development PartnerFARCO-PHARMA and Purenum GmbH have established a strategic partnership. Manfred Peschka, Managing Director of Purenum GmbH, stated that FARCO-PHARMA is the ideal partner due to its many years of experience in the field of urological gels and the resulting trust of medical specialists.
• Charité Universitätsmedizin BerlincoreStrategic or Co-development PartnerDr. med. Anja Lingnau serves as Medical Director Pediatric Urology at Charité Universitätsmedizin Berlin. She provides expert perspectives on FARCO-PHARMA products and company activities, including participation in the #NDOteenCamp initiative for young patients with neurogenic detrusor overactivity.
• DGU (Deutsche Gesellschaft für Urologie)minorOthersGerman Society of Urology organization shown in FARCO-PHARMA's commitment/partnership section, indicating industry engagement and professional society support.
• Deutsche KontinenzgesellschaftminorOthersGerman Continence Society organization shown in FARCO-PHARMA's commitment section, indicating support for continence-related medical initiatives.

Scale indicators6 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Cook Medical: Privately-held US medical device manufacturer with a dedicated urology division. Offers urological consumables and devices serving overlapping end-customer segments in hospitals and clinics.
• Coloplast: Danish medical device company specializing in urology, ostomy, and continence care. Direct competitor to FARCO-PHARMA in sterile lubricants and urology products, with overlapping customer base of healthcare providers and catheterization procedures.
• Hollister Incorporated: Privately-held US medical products manufacturer with a urology/continence care portfolio. Offers sterile intermittent catheters and urological accessories, overlapping with FARCO-PHARMA's catheter inflation and instillation therapy categories.
• Wellspect Healthcare: Swedish specialist in urology and continence care, owned by the Aragon Group. Competes directly in urological devices and intermittent catheterization - a closely adjacent product category to FARCO-PHARMA's catheter inflation solutions.
• Teleflex Incorporated: US-listed medical device company with a urology portfolio including catheters and urological care products. Overlaps with FARCO-PHARMA in urological consumables and catheter-related solutions.

Broad incumbents

• Karl Storz: German medical device manufacturer specializing in endoscopy for urology and other specialties. Indirectly comparable through Endosgel's role in endoscopic procedures, but operates in capital equipment rather than consumables.
• B. Braun: Large German medical technology and pharmaceutical company with broad portfolio including urology, infusion therapy, and pharmaceutical solutions. Larger incumbent operating broadly in the same space with overlapping sterile consumables and instillation therapies.
• Boston Scientific: Large US-listed medical device company with a Pelvic Health/urology franchise. Operates broadly across urology interventions, providing indirect competitive pressure on FARCO-PHARMA's hospital-based urology customers.

Emerging players

• Purenum GmbH: German specialty company partnering with FARCO-PHARMA on urological gel innovations. Strategic partner and emerging player in adjacent urology specialty products, with overlap in hydrogel-based medical applications.
• Convatec: UK-listed medical products company with focus on continence care, ostomy, and advanced wound care. Overlaps with FARCO-PHARMA in catheterization and continence management products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/FarcoPharma
• LinkedInlinkedin.com/company/farco-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FARCO-PHARMA